MedPath

DPP-4(Dipeptidyl peptidase-4) inhibitor Sitagliptin Phosphate Hydrate study to the inhibition of extension atherosclerosis

Not Applicable
Not yet recruiting
Conditions
Type2 diabetes mellitus (borderline)
Registration Number
JPRN-UMIN000004881
Lead Sponsor
Tokushima University Hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
All
Target Recruitment
40
Inclusion Criteria

Not provided

Exclusion Criteria

1.Has a history of allergy to Sitagliptin Phosphate Hydrate 2.Has a history of severe ketosis, diabetic coma and type1 diabetes mellitus 3.Has a history of severe renal insufficiency (hemodialysis or peritoneal dialysis patients) 4.Has a history of severe infection, perioperative term and severe wound 5.Has a overt systemic disease (liver cirrhosis, thyroid gland disease and nephrotic syndrome and so on) 6.Is not appropriate in the investigators' opinion

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath